GlassScriptPhysician profile
Rohit Kulkarni
NPI 1942853536
$15,864.48
in general payments reported to CMS, 2019-2025
14 companies · $935 in 2025
The $935 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $15K · 2025: $935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $13K · Honoraria: $1,562 · Food and Beverage: $1,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $13,243.16 |
| Honoraria | $1,561.95 |
| Food and Beverage | $1,059.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma Co., LTD. | $14,830.31 | 2024 | |
| Medtronic, INC. | $235.89 | 2024-2025 | Minimed 780g |
| Bayer Healthcare Pharmaceuticals INC. | $208.79 | 2024-2025 | |
| Insulet Corporation | $207.51 | 2025 | Omnipod, Omnipod |
| Sanofi-Aventis U.S. LLC | $139.80 | 2025 | |
| Novo Nordisk INC | $57.16 | 2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $55.49 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amphastar Pharmaceuticals, INC. | $31.48 | 2025 | |
| Lilly USA, LLC | $19.37 | 2025 | Zepbound, Mounjaro |
| Phathom Pharmaceuticals, INC. | $17.68 | 2025 | Voquezna |
| Mannkind Corporation | $16.48 | 2024 | |
| Novartis Pharmaceuticals Corporation | $15.81 | 2025 | |
| Xeris Pharmaceuticals, INC. | $15.35 | 2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.36 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Kulkarni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.